Threshold Pharmaceuticals, Inc.NASDAQ
Fri, Sep. 30, 12:50 PM
Fri, Sep. 30, 11:00 AM
Fri, Sep. 30, 9:15 AM
Thu, Sep. 29, 6:53 PM
- Threshold Pharmaceuticals (NASDAQ:THLD) has tumbled 67.8% after hours after the company published interim results from its tarloxotinib program that disappointed, and plans to discontinue that program and focus on earlier-stage opportunities.
- While the trial achieved the primary interim response rate endpoint in patients with recurrent or metastatic squamous cell carcinoma of the skin, it didn't achieve it in patients with metastatic squamous cell carcinoma of the head and neck, or with advanced EGFR-mutant, T790M-negative non-small cell lung cancer.
- The company will focus on evofosfamide, in work at the University of Texas' MD Anderson Cancer Center, as well as an earlier-stage candidate, TH-3424.
- The company will provide more operational guidance in Q4.
Tue, Sep. 6, 11:00 AM
Tue, Sep. 6, 9:14 AM
Fri, Sep. 2, 12:43 PM
Fri, Sep. 2, 12:32 PM
Tue, Aug. 30, 9:15 AM
Mon, Aug. 1, 8:34 AM
Mon, Aug. 1, 8:04 AM
Mon, Jun. 6, 7:44 AM
- As expected, the FDA informs Threshold Pharmaceuticals (NASDAQ:THLD) that the results from its Phase 3 clinical trial, EMR200592-001, and its Phase 2 study, TH-CR-404, do not provide adequate efficacy data to support a New Drug Application (NDA) seeking approval of evofosfamide for the treatment of patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma previously untreated with chemotherapy.
- The company's stock plummeted over 80% last December when the company reported that the product candidate failed two late-stage studies.
- Previously: Threshold's lead product candidate flunks two late-stage trials; shares plummet 83% (Dec. 7, 2015)
Tue, May 10, 9:06 AM
- Micro cap CytRx (NASDAQ:CYTR) slumps 8% premarket on increased volume in response to a report published this morning by TheStreet's Adam Feuerstein. He says the company's Phase 3 clinical trial assessing lead product candidate aldoxorubicin for the second-line treatment of soft tissue sarcoma (STS) will likely fail considering its similarity to doxorubicin, an older chemo drug that doesn't work well against STS. The release of top-line data is expected next month.
- The bulk of Mr. Feuerstein's pessimism is based on his take of an earlier Phase 2b study that showed treatment with aldoxorubicin doubled progression-free survival compared to doxorubicin. On closer inspection, however, the difference appeared to be due to the early termination of doxorubicin in sarcoma patients which reduced PFS and response rate to lower-than-expected levels. PFS for aldoxorubicin was comparable to earlier studies of doxorubicin so had patients been maintained on therapy, the difference in PFS would likely have been modest, certainly shy of statistical significance.
- He also cites Ziopharm's (NASDAQ:ZIOP) failure with palifosfamide and Threshold Pharmaceuticals' (NASDAQ:THLD) failure with a similar compound called evofosfamide.
- The value proposition of aldoxorubicin is greater efficacy compared to doxorubicin by virtue of its linker molecule that binds to albumin. This supposedly drives greater uptake in the tumor which enables higher dosing without the collateral damage to healthy tissue.
- Previously: CytRx hits target number of progression events in late-stage aldoxorubicin study in soft tissue cancer; shares up 14% (April 4)
Thu, May 5, 5:25 PM
- Threshold Pharmaceuticals (NASDAQ:THLD): Q1 EPS of -$0.11 misses by $0.09.
Thu, Mar. 17, 4:11 PM
Thu, Mar. 10, 4:38 PM
- Threshold Pharmaceuticals (NASDAQ:THLD): Q4 EPS of $0.86 may not be comparable to consensus of -$0.12.
- Revenue of $65.9M (+1690.8% Y/Y) beats by $61.7M.
- Shares +12.1% AH.